key: cord-0327496-89l3swt0
authors: Ren, Z.; Furukawa, K.; Nishimura, M.; Kurahashi, Y.; Sutandhio, S.; Tjan, L. H.; Aoki, K.; Hasegawa, N.; Arii, J.; Uto, K.; Matsui, K.; Sato, I.; Saegusa, J.; Godai, N.; Takeshita, K.; Yamamoto, M.; Nagashima, T.; Mori, Y.
title: Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021
date: 2021-09-28
journal: nan
DOI: 10.1101/2021.09.26.21264129
sha: 34f094fa8db07eb4d486411321781b0e293e79d8
doc_id: 327496
cord_uid: 89l3swt0

The situation of the COVID-19 pandemic in Japan is drastically changing in the 2nd year, 2021, due to the appearance of SARS-CoV-2 variants of concern and the roll-out of mass vaccination. In addition to PCR diagnosis, periodic seroepidemiologic surveillance is important to analyze the epidemic situation. In this study, we analyzed the rate of seropositivity for the SARS-CoV-2 N and S antigens in Hyogo prefecture, Japan in August 2021. Sera collected from people who received a health check-up in a clinic of the Hyogo Prefecture Health Promotion Association were subjected to analysis of reactivity to the SARS-CoV-2 N and S antigens by electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA), respectively. For a total 1,000 sera, the positive rates to N and S antigens were 2.1% and 38.7%, respectively. The infectious rate estimated by serological analysis based on the presence of the anti-N antibody was 2.5-fold higher than the value reported based on PCR-based analysis, and it increased five-fold compared to the rate determined by our previous seroepidemiologic study in October, 2020. The anti-S positive rate was almost consistent with the vaccination rate in this area. The observed high anti-S antibody level in the seropositive population may indicate that the mass vaccination in Japan is being performed smoothly at this time point, although the infectious rate has also increased.

The COVID-19 pandemic, which first emerged in December 2019, has undergone 57 several turning points, introducing drastic changes in its progress. One of the most important 58 factors is the appearance of the SARS-CoV-2 variants of concern (VOCs) replacing the original 59 variant. In Japan, the Alpha variant (B1.1.7) replaced the existing strain by around April, 2021; 60 individual's potential to be protected from the infection (29, 31) . 92

Under the current situation where infected and vaccinated people are both prevalent in 93 society, seroepidemiologic surveillance can be used to accurately measure the proportion of 94 individuals who have acquired SARS-CoV-2-specific antibodies by infection, vaccination or 95 both. Seroepidemiologic surveillance is frequently conducted to understand and predict 96 epidemics (8, 23, 26, 28, 35) . 97

In this study, we reported the 2 nd seroepidemiologic survey of COVID-19 in Hyogo 98 prefecture from July to August 2021, which overlaps with the period of the 2020 Tokyo 99

Olympics, delayed one year and held in Japan in the summer of 2021 (30). The anti-N antibody 100 positivity rate revealed that the estimated infection rate was slightly higher than that reported by 101 PCR diagnosis, whereas the anti-S antibody positive rate was consistent with the current 102 vaccination rate in Hyogo prefecture. This report will be a milestone in the era during which the 103 vaccine and SARS-CoV-2 VOCs are struggling for dominance. 104

Samples 107

Serum samples were collected from people receiving health check-ups at the clinics of Hyogo 108

Prefecture Health Promotion Association, Kobe, Japan from 19 th July to 6 th August. This 109 retrospective observational study was explained on the website of Kobe University Hospital 110 along with the opportunity to opt-out. Each serum was heat-treated at 56°C for 30 min and 111 stored in 4°C until use. 112 (N). The measurement was performed according to the manufacturer's instructions, and samples 119 with a cut-off index (COI) > 1.0 were diagnosed as positive. 120 121 Expression and purification of SARS-CoV-2 spike protein 122

The Spike protein used for the ELISA assay was prepared by a recombinant 123 expression system similar to that previously reported by another research group (15). Briefly, 124 the gene sequence of the SARS-CoV-2 Spike ectodomain (amino acids 1-1213) was subcloned 125 into a pCAGGS vector (24) with a puromycin-resistant gene. The Spike sequence used here 126 includes following mutations: D614G, R682del, R683del, R685del, F817P, A892P, A899P, 127 A942P, K986P, and V987P, and additional sequences: namely, an HRV-3c recognition site, T4 128 foldon, and a His-tag at the C-terminal side. The sequence was confirmed by the capillary 129 electrophoresis sequencer DS3000 (Hitachi High-Tech). 130

Spike protein was expressed using the Expi293 expression system (Thermofisher 131 Scientific) according to the manufacturer's instruction. The culture supernatant was collected at 132 four days post transfection. The His-tagged Spike protein was purified by Ni-NTA agarose 133 (Qiagen) and size exclusion chromatography using the Superose 6 increase column and AKTA 134 pure system (Cytiva). 135 136

Anti-Spike antibodies in the human sera were detected by an enzyme-linked 138 immunosorbent assay with the purified Spike ectodomain described above. Each well of the 96-139 well ELISA plate (Corning) was coated with 100 ng of purified Spike protein dissolved in a 140 carbonate buffer at 4°C overnight. After washing the plate with PBS containing 0.1% Tween 20 141 (PBST) to remove the antigen, PBST supplemented with 1% bovine serum albumin was added 142 as a blocking buffer followed by incubation at 4°C for 2 hours. Individual sera samples serially 143 diluted from 1:40 to 1:5120 in the blocking buffer were added to the antigen-coated plate, and 144 then incubated at 37°C for 1 hour. After washing with PBST, a goat anti-human IgG with 145 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint conjugated horseradish peroxidase (abcam) diluted 1:10000 with PBST was added as a 146 secondary antibody followed by incubation at 37°C for 1 hour. After washing with PBST, 100 μl 147 per well of ABTS solution (Roche) was added as substrate, and the plate was incubated at room 148 temperature for 40 minutes in the dark. The reaction was stopped by adding 100 μl of 1.5% 149 (w/v) oxalic acid dehydrate solution. The optical density at wavelength 405 nm (OD 405 ) was 150 measured using the plate leader Multiskan FC (Thermofisher Scientific). Based on a preliminary 151 experiment using sera from healthy volunteers (average 0.14; standard deviation: 0.022, n=12), Results 169

We collected sera from 1,000 persons who received a health check-up at a clinic of the 171

Hyogo Prefecture Health Promotion Association in Hyogo prefecture. A summary of the 172 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The age distribution was widely spread with a median of 48 (Table 1 and Figure 1A ). The 174 history of vaccination and infection were not included as selection or exclusion criteria; thus, no 175 prior information was referred to in this study. 176 177

The SARS-CoV-2 anti-N antibodies were detected by the electrochemiluminescence 179 immunoassay (ECLIA) method (10, 11), and 21 of the 1,000 samples (2.1%) were deemed 180 positive given the cut-off of 1.0 ( Table 2 ). The age distribution of positive cases is shown in 181 Figure 1B and Table 2 . The positive rate for the age groups 30-39 yrs and 40-49 yrs were 182 especially high, at 3.4% (6/179) and 4.1% (10/243), respectively. The positive rates for males 183 and females were 2.7% (16/587) and 1.2% (5/413), respectively. 184

The anti-S antibodies were detected by the enzyme-linked immunosorbent assay 185 (ELISA) method using a purified SARS-CoV-2 Spike protein. As a result, 38.7% (387/1,000) 186

were positive given the cut-off of 0.3 (See the Materials and Methods). The age distribution of 187 anti-S positive cases is shown in Figure 1C and Table 2 for the value of the anti-S antibody. As expected, all the anti-N positive sera also were anti-S 196 positive with one exception for a serum in which the N antibody detection value was also 197 relatively low, probably due to a weak immune response 198 199 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint

We further analyzed the distribution of the anti-S positive reactivity of the sera 201 because it represents the amount of anti-S antibodies related to the neutralizing antibodies 202 against SARS-CoV-2. The anti-S positive sera were further evaluated by serial dilution. 203

Representative curves are shown in Figure 3A Seroepidemiologic surveillance is a powerful approach to understanding the spread of 215 infectious diseases in combination with other methods such as PCR diagnosis and antigen tests. 216

Our surveillance in August 2021 revealed that the anti-N-positive rate, which represents the 217 SARS-CoV-2 infectious rate, was 2.1%. At the end of the surveillance, the reported infectious 218 rate based on PCR diagnosis was 0.85% and 0.80% in the Hyogo prefecture and in Japan, 219 respectively (33), indicating approximately a 2.5-fold difference compared with the result in this 220 study. The difference is accounted for by the existence of asymptomatically or mildly infected 221 individuals whose cases may not have been detected because they never underwent testing and 222 PCR analysis. Indeed, a substantial portion of SARS-CoV-2 infected individuals are 223 asymptomatic (4), leading to the inaccuracy of surveillance rates determined solely on PCR 224 diagnosis. Although it is difficult to extrapolate our data directly to the whole population, they 225

suggest that the infection is more widespread in Japan than the current PCR test results suggest 226 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint and indicate a need for more systematic testing. Nonetheless, the difference between the 227 seroepidemiologic analysis and the PCR diagnosis was not overly large; i.e., the two sets of data 228 are mutually validating. 229

The infectious rate of 2.1% revealed in this study in August 2021 is 14-fold higher 230 than the rate 0.15% we reported in our 1st seroepidemiologic analysis in October 2020 (11). The The observed high anti-S positive rate for the age groups 60-69 yrs and ≥70 yrs is 250 explained by the priority vaccination for elderly people (more than 65 years old) in Japan 251

( Figure 1C ). The high anti-S positive rate might be related to the relatively low infection rate in 252 these age groups ( Figure 1B) . However, the data for the age groups 50-59 yrs and <29 yrsr, for 253 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint which both the anti-S and ant-N positive rates were relatively low, indicated that the low 254 infectious rate could not be simply explained by the high anti-S positive rate of the age group. 255

To understand the relatively high infectious rate for the age groups 30-39 yrs and 40-49 yrs 256 shown in our data ( Figure 1B) , social reasons such as work commitments and social activities 257 may need to be taken into consideration. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted September 28, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 28, 2021. Spearman's rank correlation coefficient = 0.44

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted September 28, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted September 28, 2021. ; https://doi.org/10.1101/2021.09.26.21264129 doi: medRxiv preprint

Government CIOs' portal, Japan. COVID-19 Vaccination in Japan

Ministry of Health

Magnitude of asymptomatic COVID-19 cases throughout 336 the course of infection: A systematic review and meta-analysis

Serological markers of

-2 infection; anti-nucleocapsid antibody positivity may not be the 341 ideal marker of natural infection in vaccinated individuals

A serological assay 348 to detect SARS-CoV-2 seroconversion in humans

Efficacy and Safety of the 355 mRNA-1273 SARS-CoV-2 Vaccine

Seroprevalence of COVID-19 IgG antibodies among healthcare workers of

Evolution of antibody immunity to SARS-CoV-2

Serological surveillance of SARS-CoV-2: Six-month 389 trends and antibody response in a cohort of public health workers

Vaccine Occur Within a Week After the First Dose in Previously Infected 394 Individuals and After the Second Dose in Uninfected Individuals

Structure-based design of prefusion-stabilized SARS-CoV-2 401 spikes

Predicted dominance of variant

Delta of SARS-CoV-2 before Tokyo Olympic Games

COVID-19: A review of 406 therapeutic strategies and vaccine candidates

Side effects 409 and antibody titer transition of the BNT162b2 messenger ribonucleic acid 410 coronavirus disease 2019 vaccine in Japan

Delayed 412 COVID-19 vaccine roll-out in Japan

Effectiveness of the Pfizer-Hammitt

Safety and 436 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Antibodies and Associated Factors in Health Care Workers

Population-Based Serosurvey for

Severe Acute Respiratory Syndrome Coronavirus 2 Transmission

Acta Med 450 Comparison of SARS-CoV-2 Antibody Response Following Vaccination With 453 BNT162b2 and mRNA-1273. JAMA. 454 30. Tokuda, Y., and T. Kuniya. 2021. Prediction of COVID-19 cases during Tokyo's

462 2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating 463 variants

Impact of COVID-19 467 vaccination program on seroprevalence in blood donors in England

Difference in SARS-CoV-2 Antibody Status Between Patients

With Cancer and Health Care Workers During the COVID-19 Pandemic in

Antibody response after COVID-19 vaccine BNT162b2 on health care workers 477 in Japan

Seroprevalence of SARS-CoV-2 in 480